Clinical trials: Cancer, Carcinoma
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Carcinoma, Squamous Cell, Cancer of the Head and Neck
Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck
This research is being done because we do not know the best treatment for advanced Squamous Cell Carcinoma of the Head and Neck.
- Trial name
- HBO-XRT (NCT00474825)
- Testing
- Hyperbaric Oxygen Therapy, Hyperbaric Oxygen
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- National Baromedical Services
Carcinoma, Renal Cell
Hepatic Monitoring for Pazopanib
Pazopanib is approved by the FDA and EMA as targeted therapy for the indication of advanced renal cell carcinoma (RCC). Hepatic safety events were observed in the pazopanib pivotal clinical trial and the U.S.
- Trial name
- NCT01449825
- Testing
- Pazopanib use, Use of sunitinib, bevacizumab, or sorafenib
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Esophageal Neoplasms
Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection
The LOCARE-Trial is an investigator initiated, randomized-controlled trial with two parallel arms (n=60 each) and investigates the influence of esophageal washout on long-term outcomes in patients undergoing elective esophageal…
- Trial name
- LOCARE (NCT02676791)
- Testing
- Povidone-Iodine
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Technische Universität Dresden
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT05929768
- Testing
- Biospecimen Collection, Carboplatin, Cyclophosphamide
- Where
- 963 sites in United States, Mexico and 1 more
- Volunteers
- 2,400 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Carcinoma, Fallopian Tube Carcinoma
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- PGA (NCT01936974)
- Testing
- Gemcitabine, Bevacizumab, Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Western Regional Medical Center
Non Small Cell Lung Cancer
A Study for Patients With Non-Squamous Non-Small Cell Lung Cancer
Chemotherapy for patients with non-squamous non-small cell lung cancer. Patients are given folic acid, vitamin B12 and steroids, both before and during treatment, to reduce the side effects associated with pemetrexed.
- Trial name
- NCT00609518
- Testing
- pemetrexed, Folic acid, Vitamin B12
- Where
- 14 sites in Australia, Italy and 2 more
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
Anal Cancer, Squamous Intraepithelial Lesions
Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis
This study aims to learn more about anal cancer risk in men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) to prevent HIV.
- Conditions
- Anal Cancer, Squamous Intraepithelial Lesions, HSIL, High Grade Squamous Intraepithelial Lesions, LSIL, Low-Grade Squamous Intraepithelial Lesions
- Trial name
- SCOPE (NCT07029152)
- Testing
- Anal smear, Self-administered questionnaire, EQ-5D-5L questionnaire
- Where
- 8 sites in Belgium
- Volunteers
- 296 people
- Sponsor
- Universitair Ziekenhuis Brussel
NSCLC (Advanced Non-small Cell Lung Cancer), Adaptive Radiotherapy
Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer
Locally advanced non-small cell lung cancer (LA-NSCLC) patients could benefit in overall and progression-free survival from regular dosimetric treatment plan adaptations during radiotherapy.
- Trial name
- ECLAIR (NCT07259447)
- Testing
- CBCT-based adaptive radiotherapy
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colorectal Cancer, Colorectal Carcinoma
Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- PIE (NCT01139138)
- Testing
- Panitumumab, Irinotecan, Everolimus
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- The Queen Elizabeth Hospital
Lung Cancer
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00533585
- Testing
- BAY 43-9006, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Breast Cancer, Esophageal Cancer
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells.
- Conditions
- Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT00003125
- Testing
- ALVAC-CEA vaccine, aldesleukin, sargramostim
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Georgetown University
Head and Neck Squamous Cell Carcinoma, Melanoma
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer
- Trial name
- NCT04762225
- Testing
- RPTR-168
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Repertoire Immune Medicines
Carcinoma, Non-Small-Cell Lung, Docetaxel
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
This study is a randomized, single-center, open-label, phase II clinical trial designed to evaluate non-small cell lung cancer that has failed to undergo excessive platinum-based chemotherapy and has not received excessive statin…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Docetaxel, Nivolumab
- Trial name
- NCT04023617
- Testing
- Nivolumab
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non Small Cell Lung Cancer
Erlotinib and Sunitinib in NSCLC
To determine the safety and maximally tolerated dose of sunitinib plus erlotinib in patients with non-small cell lung cancer (NSCLC). To determine response to sunitinib plus erlotinib in patients with non-small cell lung cancer.
- Trial name
- NCT00581789
- Testing
- erlotinib, sunitinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Breast Cancer
A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel
This is a multicentre, multinational Phase Ib study in female HR+ MBC patients not receiving Her2-targeted therapy. Treatment consists of a chemo-immunotherapy phase followed by a maintenance phase.
- Trial name
- AIPAC-002 (NCT04252768)
- Testing
- Eftilagimod Alpha, Paclitaxel
- Sponsor
- Immutep S.A.S.
Head and Neck Neoplasms, Lung Neoplasms
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Background: Two experimental drugs, FdCyd (also called 5-fluoro-2'-deoxcytidine), and THU (also called tetrahydrouridine), are undergoing trials to test their effectiveness in treating cancer that has not responded to standard…
- Conditions
- Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
- Trial name
- NCT00978250
- Testing
- 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
- Where
- 4 sites in United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer Extensive Stage
Liposomal Irinotecan and Apatinib in ES-SCLC
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
- Trial name
- LIAES (NCT06749691)
- Testing
- Liposomal Irinotecan and Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.